Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Jean-François Pujol | M | - |
Biocortech SAS
 Biocortech SAS Pharmaceuticals: MajorHealth Technology Biocortech SAS discovers and develops drug therapies for brain disorders. The company is engaged in treating pathologies and focuses its R&D program on depression, schizophrenia and cognitive deficits. Biocortech develops pharmaceuticals for deficient pathways in the adult brain or deficient receptors via the modulation of RNA editing mechanisms. The company was founded by Dinah Weissmann in 2001 and is headquartered in Paris, France. | - |
| Jean-Paul Leon | M | - |
Biocortech SAS
Biocortech SAS Pharmaceuticals: MajorHealth Technology Biocortech SAS discovers and develops drug therapies for brain disorders. The company is engaged in treating pathologies and focuses its R&D program on depression, schizophrenia and cognitive deficits. Biocortech develops pharmaceuticals for deficient pathways in the adult brain or deficient receptors via the modulation of RNA editing mechanisms. The company was founded by Dinah Weissmann in 2001 and is headquartered in Paris, France. | - |
| Samuel Bengio | M | - |
Biocortech SAS
Biocortech SAS Pharmaceuticals: MajorHealth Technology Biocortech SAS discovers and develops drug therapies for brain disorders. The company is engaged in treating pathologies and focuses its R&D program on depression, schizophrenia and cognitive deficits. Biocortech develops pharmaceuticals for deficient pathways in the adult brain or deficient receptors via the modulation of RNA editing mechanisms. The company was founded by Dinah Weissmann in 2001 and is headquartered in Paris, France. | - |
| Frédéric Allemand | M | - |
Biocortech SAS
Biocortech SAS Pharmaceuticals: MajorHealth Technology Biocortech SAS discovers and develops drug therapies for brain disorders. The company is engaged in treating pathologies and focuses its R&D program on depression, schizophrenia and cognitive deficits. Biocortech develops pharmaceuticals for deficient pathways in the adult brain or deficient receptors via the modulation of RNA editing mechanisms. The company was founded by Dinah Weissmann in 2001 and is headquartered in Paris, France. | - |
Connections Chart
Multi-company connection
Statistics
| Country | Connections | % of total |
|---|---|---|
| France | 4 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Daniel Larzul
- Personal Network
